Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia Recruiting Phase 1 / 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0114145 (Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01751425Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTreatment